Literature DB >> 16645588

Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells.

Alexander Roesch1, Bernd Becker, Wulf Schneider-Brachert, Ilja Hagen, Michael Landthaler, Thomas Vogt.   

Abstract

The loss of cell cycle control in malignant melanomas is thought to be due to a lack of retinoblastoma protein (pRb) activity. We have recently reported a progressive deficiency of the retinoblastoma-binding protein 2-homolog 1 (RBP2-H1) in advanced and metastatic melanomas in vivo, suggesting a role of RBP2-H1 in loss of pRb-mediated control. Therefore, in this study, we re-established the pRb-modulating function of RBP2-H1 in highly metastatic A375-SM melanoma cells by re-expressing its C-term (cRBP2-H1). As previously shown, the corresponding domains comprise the pRb-binding region of the RBP2-H1 protein (non-T/E1A-pRb-binding domain (NTE1A)). As a result, we detected pRb-hypophosphorylation selectively at Ser795, but not at Ser780 and Ser807/811 throughout the G1 phase of the cell cycle. As a further consequence, a block in G1/S transition was observed accompanied by a significant decrease of DNA replication and cellular proliferation. As demonstrated by cDNA microarrays of cRBP2-H1-transduced cells and confirmed by quantitative TaqMan reverse transcriptase-PCR, differential expression of melanoma-progression-related genes was observed, among them bone morphogenetic protein 2, follistatin, transforming growth factor alpha, hepatocyte growth factor, transcription factor 4 and microphthalmia-associated transcription factor. Conclusively, these data suggest that RBP2-H1 exerts a broad tumor-suppressive function partially mediated by pRb modulation. Therefore, re-establishing of RBP2-H1 could evolve as an interesting novel approach in developing experimental treatments for metastatic melanomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16645588     DOI: 10.1038/sj.jid.5700324

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  21 in total

1.  Histone demethylase PHF8 promotes progression and metastasis of gastric cancer.

Authors:  Shuyan Li; Ao Sun; Xiuming Liang; Lin Ma; Li Shen; Tongyu Li; Lixin Zheng; Wenjing Shang; Wei Zhao; Jihui Jia
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

2.  A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Authors:  Alexander Roesch; Mizuho Fukunaga-Kalabis; Elizabeth C Schmidt; Susan E Zabierowski; Patricia A Brafford; Adina Vultur; Devraj Basu; Phyllis Gimotty; Thomas Vogt; Meenhard Herlyn
Journal:  Cell       Date:  2010-05-14       Impact factor: 41.582

3.  Genetic loci that regulate healing and regeneration in LG/J and SM/J mice.

Authors:  Elizabeth P Blankenhorn; Gregory Bryan; Andrew V Kossenkov; Lise Desquenne Clark; Xiang-Ming Zhang; Celia Chang; Wenhwai Horng; L Susan Pletscher; James M Cheverud; Louise C Showe; Ellen Heber-Katz
Journal:  Mamm Genome       Date:  2009-09-16       Impact factor: 2.957

Review 4.  Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?

Authors:  Nayoung Lee; Steven R Barthel; Tobias Schatton
Journal:  Lab Invest       Date:  2013-10-14       Impact factor: 5.662

Review 5.  The role of histone demethylases in cancer therapy.

Authors:  Inga Hoffmann; Martin Roatsch; Martin L Schmitt; Luca Carlino; Martin Pippel; Wolfgang Sippl; Manfred Jung
Journal:  Mol Oncol       Date:  2012-08-07       Impact factor: 6.603

6.  HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.

Authors:  I-Ju Yeh; Kyung Song; Bryan M Wittmann; Xiaodong Bai; David Danielpour; Monica M Montano
Journal:  Biochem J       Date:  2014-09-01       Impact factor: 3.857

7.  Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10.

Authors:  Joanna Kim; Sook Shin; Malayannan Subramaniam; Elizabeth Bruinsma; Tae-Dong Kim; John R Hawse; Thomas C Spelsberg; Ralf Janknecht
Journal:  Biochem Biophys Res Commun       Date:  2010-09-20       Impact factor: 3.575

8.  JARID1B is a luminal lineage-driving oncogene in breast cancer.

Authors:  Shoji Yamamoto; Zhenhua Wu; Hege G Russnes; Shinji Takagi; Guillermo Peluffo; Charles Vaske; Xi Zhao; Hans Kristian Moen Vollan; Reo Maruyama; Muhammad B Ekram; Hanfei Sun; Jee Hyun Kim; Kristopher Carver; Mattia Zucca; Jianxing Feng; Vanessa Almendro; Marina Bessarabova; Oscar M Rueda; Yuri Nikolsky; Carlos Caldas; X Shirley Liu; Kornelia Polyak
Journal:  Cancer Cell       Date:  2014-06-16       Impact factor: 31.743

9.  Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies.

Authors:  Luca Sigalotti; Alessia Covre; Elisabetta Fratta; Giulia Parisi; Francesca Colizzi; Aurora Rizzo; Riccardo Danielli; Hugues J M Nicolay; Sandra Coral; Michele Maio
Journal:  J Transl Med       Date:  2010-06-11       Impact factor: 5.531

10.  Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.

Authors:  Alexander Roesch; Adina Vultur; Ivan Bogeski; Huan Wang; Katharina M Zimmermann; David Speicher; Christina Körbel; Matthias W Laschke; Phyllis A Gimotty; Stephan E Philipp; Elmar Krause; Sylvie Pätzold; Jessie Villanueva; Clemens Krepler; Mizuho Fukunaga-Kalabis; Markus Hoth; Boris C Bastian; Thomas Vogt; Meenhard Herlyn
Journal:  Cancer Cell       Date:  2013-06-10       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.